Published in Antimicrob Agents Chemother on July 01, 1992
Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother (1994) 3.96
Current perspectives on glycopeptide resistance. Clin Microbiol Rev (1995) 2.99
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother (1994) 2.76
In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob Agents Chemother (1996) 2.76
In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004. Antimicrob Agents Chemother (1997) 2.65
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother (1996) 1.90
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother (1996) 1.76
Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob Agents Chemother (1997) 1.70
In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob Agents Chemother (1993) 1.54
Survey of in vitro susceptibilities of Vibrio cholerae O1 and O139 to antimicrobial agents. Antimicrob Agents Chemother (1995) 1.54
Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system. Antimicrob Agents Chemother (1993) 1.53
In vitro activity of fluoroquinolones against gram-positive bacteria. Drugs (1995) 1.46
Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother (1995) 1.40
In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob Agents Chemother (1994) 1.31
Bactericidal activity of DU-6859a compared to activities of three quinolones, three beta-lactams, clindamycin, and metronidazole against anaerobes as determined by time-kill methodology. Antimicrob Agents Chemother (1997) 1.16
In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother (1995) 1.12
Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene. Antimicrob Agents Chemother (1996) 1.10
Comparative in vitro activity of DU-6859a, a new fluoroquinolone agent, against gram-positive cocci. Antimicrob Agents Chemother (1994) 1.04
In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother (1995) 1.02
In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother (1994) 0.99
The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae. Drugs (1995) 0.97
Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases. Antimicrob Agents Chemother (1998) 0.95
Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteers. Antimicrob Agents Chemother (1998) 0.93
Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother (1997) 0.92
Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother (1999) 0.91
Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations. Antimicrob Agents Chemother (2009) 0.83
Bactericidal activity of the fluoroquinolone WIN 57273 against high-level gentamicin-resistant Enterococcus faecalis. Antimicrob Agents Chemother (1993) 0.82
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother (2011) 0.78
Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci. Antimicrob Agents Chemother (1994) 0.75
Population pharmacokinetics and pharmacodynamics of sitafloxacin in patients with community-acquired respiratory tract infections. J Infect Chemother (2013) 0.75
Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Antimicrob Agents Chemother (1998) 0.75
In vitro and in vivo activities of sitafloxacin against Chlamydia spp. Antimicrob Agents Chemother (2001) 0.75
Antibacterial activities and pharmacokinetics of E-4767 and E-5065, two new 8-chlorofluoroquinolones with a 7-azetidin ring substituent. Antimicrob Agents Chemother (2001) 0.75
Activity of new 4-quinolones in combination with erythromycin or tetracycline against S. pneumoniae. Drugs (1995) 0.75
Activity of DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and OPC-17116 against 112 penicillin-susceptible and -resistant pneumococci. Drugs (1995) 0.75
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother (1983) 21.48
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother (1985) 11.34
The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother (1985) 6.44
Determination of minimum bactericidal concentrations of oxacillin for Staphylococcus aureus: influence and significance of technical factors. Antimicrob Agents Chemother (1983) 5.10
In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother (1989) 4.38
In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother (1988) 3.52
Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother (1989) 2.80
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother (1988) 2.52
Bacterial resistance to quinolones: mechanisms and clinical importance. Rev Infect Dis (1989) 2.23
In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother (1990) 1.98
Comparative in vitro activity of a new quinolone, AM-1091. Antimicrob Agents Chemother (1989) 1.78
Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients. J Antimicrob Chemother (1986) 1.24
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
The complete nucleotide sequence of the tobacco chloroplast genome: its gene organization and expression. EMBO J (1986) 19.59
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and genomic comparison with a laboratory strain K-12. DNA Res (2001) 15.22
Positional cloning of the mouse circadian clock gene. Cell (1997) 7.79
Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell (1994) 7.23
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol (2001) 6.83
Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 6.61
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature (1970) 5.65
The Oct-1 homoeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature (1989) 5.43
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Coding of modified body schema during tool use by macaque postcentral neurones. Neuroreport (1996) 3.78
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet (1989) 3.69
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol (2001) 3.26
Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation (1995) 3.18
Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A (1996) 2.88
FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell (2000) 2.86
Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. Nucleic Acids Res (1995) 2.79
Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother (1986) 2.74
Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol (1994) 2.74
Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum (2000) 2.72
Frequency of a 22q11 deletion in patients with conotruncal cardiac malformations: a prospective study. Eur J Pediatr (1995) 2.66
Risk of poliomyelitis importation and re-emergence in Laos. Lancet (2000) 2.64
Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds. Proc Natl Acad Sci U S A (1975) 2.60
Rapid identification of dengue virus serotypes by using polymerase chain reaction. J Clin Microbiol (1991) 2.60
Mitochondrial genotype associated with longevity. Lancet (1998) 2.58
Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44
Activation of protein kinase C by tyrosine phosphorylation in response to H2O2. Proc Natl Acad Sci U S A (1997) 2.42
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol (2000) 2.41
IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A (1999) 2.35
A TBP complex essential for transcription from TATA-less but not TATA-containing RNA polymerase III promoters is part of the TFIIIB fraction. Cell (1992) 2.32
Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J (1997) 2.28
Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun (1989) 2.23
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Six chloroplast genes (ndhA-F) homologous to human mitochondrial genes encoding components of the respiratory chain NADH dehydrogenase are actively expressed: determination of the splice sites in ndhA and ndhB pre-mRNAs. Mol Gen Genet (1987) 2.14
Function of Light in the Light-induced Geotropic Response in Zea Roots. Plant Physiol (1981) 2.13
Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis (1992) 2.12
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 2.11
Convulsions after ropivacaine 300 mg for brachial plexus block. Br J Anaesth (2008) 2.09
Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res (1998) 2.08
Concordance between telepathologic diagnosis and conventional histopathologic diagnosis: a multiobserver store-and-forward study on 20 skin specimens. Arch Dermatol (2002) 2.07
International transmission of uncompressed endoscopic surgery images via superfast broadband Internet connections. Surg Endosc (2005) 2.05
Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun (2000) 2.05
Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology (1999) 2.05
New neuropeptides containing carboxy-terminal RFamide and their receptor in mammals. Nat Cell Biol (2000) 2.05
Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol (2000) 2.05
Therapeutic hypercapnia reduces pulmonary and systemic injury following in vivo lung reperfusion. Am J Respir Crit Care Med (2000) 2.05
Molecular bases of odor discrimination: Reconstitution of olfactory receptors that recognize overlapping sets of odorants. J Neurosci (2001) 2.04
Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother (1987) 2.03
Poly(L-proline)-binding proteins from chick embryos are a profilin and a profilactin. Eur J Biochem (1985) 2.01
The internal biliary fistula--reappraisal of incidence, type, diagnosis and management of 33 consecutive cases. HPB Surg (1997) 2.00
Internet-based program for automatic discrimination of dermoscopic images between melanomas and Clark naevi. Br J Dermatol (2004) 1.99
Symptomatic myopathy associated with interferon therapy for chronic hepatitis C. Lancet (1995) 1.99
Erythroid cell differentiation: murine erythroleukemia cell variant with unique pattern of induction by polar compounds. Proc Natl Acad Sci U S A (1976) 1.99
Synthesis and antibacterial activities of substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acids. Chem Pharm Bull (Tokyo) (1984) 1.99
Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet (2000) 1.99
Mitochondrial mutation in fatal infantile cardiomyopathy. Lancet (1990) 1.98
Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med (2001) 1.98
Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse. Neuron (1998) 1.96
Afadin: A key molecule essential for structural organization of cell-cell junctions of polarized epithelia during embryogenesis. J Cell Biol (1999) 1.96
Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke (2000) 1.94
Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.93
Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res (1991) 1.92
Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene (1999) 1.91
Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Commun (1995) 1.90
Physical and functional mapping of Tn2603, a transposon encoding ampicillin, streptomycin, sulfonamide, and mercury resistance. Mol Gen Genet (1981) 1.88
Resistance of Fc receptor- deficient mice to fatal glomerulonephritis. J Clin Invest (1998) 1.88
Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A (1990) 1.87
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86
Antimycoplasmal activity of ofloxacin (DL-8280). Antimicrob Agents Chemother (1983) 1.86
IL-18 induction of IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol (2000) 1.86
Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.84
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer (2009) 1.84
Genes for the eight ribosomal proteins are clustered on the chloroplast genome of tobacco (Nicotiana tabacum): similarity to the S10 and spc operons of Escherichia coli. Proc Natl Acad Sci U S A (1986) 1.83
Transposition of the oxacillin-hydrolyzing penicillinase gene. J Bacteriol (1981) 1.82
Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med (1997) 1.80
Structures of mollusc shell framework proteins. Nature (1997) 1.80
A tobacco chloroplast DNA sequence possibly coding for a polypeptide similar to E. coli RNA polymerase beta-subunit. FEBS Lett (1986) 1.79
Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood (1999) 1.79
Cardiac and extracardiac expression of Csx/Nkx2.5 homeodomain protein. Circ Res (1998) 1.78
End-to-side neurorrhaphy with removal of the epineurial sheath: an experimental study in rats. Plast Reconstr Surg (1994) 1.78
When overexpressed, a novel centrosomal protein, RanBPM, causes ectopic microtubule nucleation similar to gamma-tubulin. J Cell Biol (1998) 1.78
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother (2001) 1.77
Evolution of complex resistance transposons from an ancestral mercury transposon. J Bacteriol (1983) 1.76
Normotensive salt sensitivity: effects of race and dietary potassium. Hypertension (1999) 1.74
Differential positive control by Oct-1 and Oct-2: activation of a transcriptionally silent motif through Oct-1 and VP16 corecruitment. Genes Dev (1993) 1.71